RRC ID 36959
Author Kaku Y, Tsuchiya A, Kanno T, Nishizaki T.
Title Irinotecan induces cell cycle arrest, but not apoptosis or necrosis, in Caco-2 and CW2 colorectal cancer cell lines.
Journal Pharmacology
Abstract Irinotecan, a topoisomerase I inhibitor, is clinically used as an anticancer drug. The present study investigated the anticancer effect of irinotecan on p53-negative Caco-2 and p53-positive CW2 human colorectal cancer cell lines. Cell viability for both Caco-2 and CW2 cells was little affected by treatment with irinotecan at concentrations ranging from 0.3 to 30 μmol/l for 24-48 h. Irinotecan did not increase the number of TUNEL-positive cells and did not affect the population of propidium iodide (PI)-positive and annexin V-negative cells, corresponding to primary necrosis, or that of PI-positive and annexin-positive cells, corresponding to late apoptosis/secondary necrosis, in either of the two cell lines. In the cell cycle analysis, irinotecan significantly increased the proportions at the S and G2/M phases of cell cycling in parallel with a decreased population at the G1 phase in both cell lines. Irinotecan significantly inhibited tumor growth in mice inoculated with CW2 cells. Taken together, these results indicate that irinotecan induces cell cycle arrest, but not apoptosis or necrosis, both in Caco-2 and CW2 cells, leading to suppression of cell proliferation.
Volume 95(3-4)
Pages 154-9
Published 2015-1-1
DOI 10.1159/000381029
PII 000381029
PMID 25833236
MeSH Animals Antineoplastic Agents, Phytogenic / pharmacology* Antineoplastic Agents, Phytogenic / therapeutic use Apoptosis / drug effects Caco-2 Cells Camptothecin / analogs & derivatives* Camptothecin / pharmacology Camptothecin / therapeutic use Cell Cycle Checkpoints / drug effects* Cell Line, Tumor Humans Irinotecan Male Mice, Nude Necrosis Neoplasms / drug therapy Neoplasms / pathology Tumor Burden / drug effects
IF 1.625
Times Cited 8
WOS Category PHARMACOLOGY & PHARMACY
Resource
Human and Animal Cells CACO-2(RCB0988) CW-2(RCB0778)